{"doi":"10.4049/immunohorizons.2200045","title":"Alboserpin, the Main Salivary Anticoagulant from the Disease Vector <i>Aedes albopictus</i>, Displays Anti–FXa-PAR Signaling In Vitro and In Vivo","abstract":"Abstract Blood-feeding arthropods secrete potent salivary molecules, which include platelet aggregation inhibitors, vasodilators, and anticoagulants. Among these molecules, Alboserpin, the major salivary anticoagulant from the mosquito vector Aedes albopictus, is a specific inhibitor of the human coagulation factor Xa (FXa). In this study, we investigated the anti-inflammatory properties of Alboserpin, in vitro and in vivo. In vitro, Alboserpin inhibited FXa-induced protease-activated receptor (PAR)-1, PAR-2, PAR-3, VCAM, ICAM, and NF-κB gene expression in primary dermal microvascular endothelial cells. Alboserpin also prevented FXa-stimulated ERK1/2 gene expression and subsequent inflammatory cytokine release (MCP-1, TNF-α, IL-6, IL-8, IL-1β, IL-18). In vivo, Alboserpin reduced paw edema induced by FXa and subsequent release of inflammatory cytokines (CCL2, MCP-1, IL-1α, IL-6, IL-1β). Alboserpin also reduced FXa-induced endothelial permeability in vitro and in vivo. These findings show that Alboserpin is a potent anti-inflammatory molecule, in vivo and in vitro, and may play a significant role in blood feeding.","journal":"ImmunoHorizons","year":2022,"id":278677,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9594,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":363404,"name":"Paola Carolina Valenzuela Leon","orcid":"0000-0002-5740-5178","position":1,"is_corresponding":false},{"id":471780,"name":"Andrezza Campos Chagas","orcid":"0000-0001-5187-067X","position":2,"is_corresponding":false},{"id":363401,"name":"Olivia Kern","orcid":"0000-0003-3577-5423","position":3,"is_corresponding":false},{"id":951707,"name":"Karina Botello","orcid":null,"position":4,"is_corresponding":false},{"id":348997,"name":"Yixiang Zhang","orcid":"0000-0003-3422-8436","position":5,"is_corresponding":false},{"id":363400,"name":"Inés Martín-Martín","orcid":"0000-0002-0956-7324","position":6,"is_corresponding":false},{"id":727628,"name":"Markus Berger Oliveira","orcid":"0000-0001-7670-2584","position":7,"is_corresponding":false},{"id":299545,"name":"Lucas Tirloni","orcid":"0000-0003-4582-7100","position":8,"is_corresponding":false},{"id":294696,"name":"Eric Calvo","orcid":"0000-0001-7880-2730","position":9,"is_corresponding":false},{"id":458542,"name":"Gaurav Shrivastava","orcid":"0000-0003-3229-4106","position":0,"is_corresponding":true}],"reference_count":67,"raw_metadata":null,"created_at":"2026-07-19T00:28:47.357993Z","pmid":"35738824","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}